Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | CLK1 | P49759 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5504692 | 0.87 | MCL1 (0.64) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5505981 | 0.79 | KDM4E (0.50) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5507402 | 0.79 | HSD17B10 (0.50) | KDM4EALDH1A1HPGDHSD17B10CLK1 | |
| SCHEMBL418126 | 0.77 | MCL1 (1.00) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL16440985 | 0.77 | MCL1 (0.76) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3534182 | 0.76 | MCL1 (0.73) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5507214 | 0.74 | SRD5A2 (0.71) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL31435640 | 0.74 | MCL1 (0.69) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1096760 | 0.74 | L3MBTL1 (0.70) | MCL1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL10084917 | 0.74 | MCL1 (0.69) | MCL1KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101035521-A | Cyclic and acyclic propenones for treating CNS disorders | MERZ PHARMA GMBH & CO KGAA (DE) | 2007-09-12 | — | — | CN | claimed |
| EP-1804781-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | Merz Pharma GmbH & Co.KGaA (DE) | 2007-07-11 | — | — | EP | claimed |
| WO-2006037996-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-13 | — | — | WO | claimed |
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-06 | — | — | US | claimed |
| CN-101035521-A | Cyclic and acyclic propenones for treating CNS disorders | MERZ PHARMA GMBH & CO KGAA (DE) | 2007-09-12 | — | — | CN | disclosed |
| EP-1804781-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | Merz Pharma GmbH & Co.KGaA (DE) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006037996-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006037996-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | PMP22, ADCYAP1R1, CYP11B2 | MCL1 2484/4885KDM4E 3234/4885ALDH1A1 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.